Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.93 CAD | -5.30% | -17.26% | -0.51% |
May. 09 | Transcript : HLS Therapeutics Inc., Q1 2024 Earnings Call, May 09, 2024 | |
May. 09 | HLS Therapeutics Meets Q1 Earnings Forecast, But Misses on Revs; Lowers 2024 Vascepa Guidance | MT |
Sales 2024 * | 59.65M 81.54M | Sales 2025 * | 72.37M 98.93M | Capitalization | 91.72M 125M |
---|---|---|---|---|---|
Net income 2024 * | -20M -27.34M | Net income 2025 * | -17M -23.24M | EV / Sales 2024 * | 1.54 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.27 x |
P/E ratio 2024 * |
-4.43
x | P/E ratio 2025 * |
-7.99
x | Employees | 91 |
Yield 2024 * |
5.15% | Yield 2025 * |
-
| Free-Float | 99.51% |
Latest transcript on HLS Therapeutics Inc.
1 day | -5.30% | ||
1 week | -17.26% | ||
Current month | -15.48% | ||
1 month | -23.39% | ||
3 months | -5.07% | ||
6 months | -3.44% | ||
Current year | -0.51% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Millian
CEO | Chief Executive Officer | 56 | 23-04-30 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Ryan Lennox
CMP | Compliance Officer | 43 | 18-05-06 |
Members of the board | Title | Age | Since |
---|---|---|---|
John Welborn
CHM | Chairman | 46 | 21-06-17 |
Laura Brege
BRD | Director/Board Member | 66 | 19-03-20 |
John Hanna
DFI | Director of Finance/CFO | - | 23-06-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-10 | 3.93 | -5.30% | 7,370 |
24-05-09 | 4.15 | -13.18% | 4,100 |
24-05-08 | 4.78 | +1.06% | 10,600 |
24-05-07 | 4.73 | -0.84% | 1,200 |
24-05-06 | 4.77 | +0.42% | 1,700 |
Delayed Quote Toronto S.E., May 10, 2024 at 03:59 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.51% | 91.72M | |
+20.94% | 72.78B | |
-1.26% | 24.24B | |
+8.25% | 8.38B | |
+5.13% | 8.59B | |
-19.42% | 8.09B | |
+5.56% | 4.81B | |
+16.83% | 4.32B | |
-1.83% | 4.05B | |
-1.65% | 3.93B |
- Stock Market
- Equities
- HLS Stock